Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362192 · ClinicalTrials.gov registry record · Phase 4
Treatment of Lower Extremity Spider Veins With Excel V
A Phase 4 study, sponsored by Cutera.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01362192 is a Phase 4 study that has completed, run by Cutera. The registered enrollment target is 20 participants.
The verdict
NCT01362192, a Phase 4 study, has completed, sponsored by Cutera.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of a new laser for the removal of unsightly spider veins on the legs. The device used in this study is the Cutera Excel V laser, which is a dual wavelength 532 nm potassium titanyl phosphate (KTP) and 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. The Excel V laser has received 510(k) clearance from the FDA, which means the FDA has approved the laser for dermatological and vascular conditions, like spider veins.
Interventions
- DEVICE 532 nm KTP Excel V Laser, manufactured by Cutera, Inc.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362192
The ClinicalTrials.gov registry entry for NCT01362192 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cutera, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 532 nm KTP Excel V Laser, manufactured by Cutera, Inc. is the first listed.
NCT01362192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362192 about?
NCT01362192 is a clinical study titled "Treatment of Lower Extremity Spider Veins With Excel V". The purpose of this study is to evaluate the safety and effectiveness of a new laser for the removal of unsightly spider veins on the legs. The device used in this study is the Cutera Excel V laser, which is a dual wavelength 532 nm potassium titanyl phosphate (KTP) and 1064 nm neodymium-doped yttri...
What is the current status of trial NCT01362192?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01362192?
The interventions under investigation include: 532 nm KTP Excel V Laser, manufactured by Cutera, Inc. (DEVICE).
Who is sponsoring clinical trial NCT01362192?
This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.